• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation
  • A Phase 1/2 Randomized, Dose-Finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis

Disease
multiple sclerosis
Drug Name
MEDI-551
Generic Name
MEDI-551
Sponsor
MedImmune
Drug Status
In Development
Phase
I/II
Start Date
May 1, 2012
Study Name
CD-IA-MEDI-551-1102
Study Id
CD-IA-MEDI-551-1102
ClinicalTrials.gov ID
NCT01585766
Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013